Phase 3 Spinal Muscular Atrophy Clinical Trials

4 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 1–4 of 4 trials

Recruiting

Phase 3

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

Spinal Muscular Atrophy

Biogen90 enrolled1 locationNCT07444476

Recruiting

Phase 3

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

Spinal Muscular Atrophy (SMA)

Novartis Pharmaceuticals175 enrolled32 locationsNCT05335876

Recruiting

Phase 3

Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).

Spinal Muscular Atrophy (SMA)

Lantu Biopharma15 enrolled1 locationNCT07265232

Recruiting

Phase 3

Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III

SMA - Spinal Muscular Atrophy

GeneCradle Inc50 enrolled7 locationsNCT06971094